$SER News

Serina Therapeutics Files Prospectus For Offering 16.45M Common Shares On Behalf Of Selling Stockholders

Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Serina Therapeutics Says Phase 1b Registrational Clinical Study of SER-252 Underway In Advanced Parkinson's Disease; TFL Data From The SAD Study Arm Targeted For First Half of 2027

Serina Therapeutics Q1 EPS $(0.58) Misses $(0.44) Estimate

Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit

Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan

NYSE Accepts Serina Therapeutics Plan To Regain Compliance

NYSE Accepts Serina Therapeutics Plan To Regain Compliance

Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

Serina Therapeutics Q4 EPS $(0.31) Beats $(0.46) Estimate

Serina Therapeutics to Present at the 38th Annual Roth Conference

Serina Therapeutics Appoints Gregory H. Bailey As Co-Chairman

Serina Therapeutics shares are trading higher. The company announced it entered into a $30 million private placement.

Serina Therapeutics (SER) Stock Surges Over 39% After Hours— Here's Why

Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson’s Disease

Serina Therapeutics shares are trading higher. The company announced it entered into a $30 million private placement.

Serina Therapeutics Announces Up To $30M In Private Placement To Support Registrational Trial Of SER-252 Parkinson's Treatment

Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease

Serina Therapeutics Doses First Patient In Phase 1b Registrational Clinical Trial Evaluating SER-252 In Patients With Advanced Parkinson's Disease

Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease